Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - Priority Announcement: Hepatitis C - biomedical/clinical

University of Toronto

$133,475.00

A pharmacoeconomic policy model for hepatitis C: development and applications

FY 2010-11

Summary
Hepatitis C virus (HCV) infection results in more lost life years than any other infectious disease in Ontario.1 The burden of HCV infection is growing in Canada.2,3 Existing preventive and therapeutic efforts are inadequate. However, the role of medications in disease control is not well appreciated. Current standard of care for chronic hepatitis C with pegylated interferon (PEG-IFN) alfa and ribavirin results in a cure (sustained virological response (SVR)) in less than half of people with HCV genotype 1 infection,4 which is the most prevalent genotype in Canada.5 Fewer than 15% of infected individuals have received treatment to date.6 There remains a huge burden of untreated HCV as well as those who failed previous treatment in Canada. The landscape of HCV therapy is changing because of the recent development of direct-acting antiviral agents (DAAs), with improved response rates and shorter and better tolerated therapy than the current standard of care, particularly for HCV genotype 1 infection. Therefore policymakers have complex challenges. Decision makers need to know if new medications should be paid for, while public health professionals need to incorporate the effects of treatment on disease control. Insights from mathematical modelling incorporating the effect of HCV treatment as a control strategy and model-based cost-effectiveness analysis (CEA) can support policy decision-makers and health service planners by predicting how much improvement in health can be expected for a given expenditure of resources. Our project aims to: i) evaluate the cost-effectiveness of DAA (telaprevir and boceprevir) therapeutic strategies in various clinical populations; and ii) evaluate the population health impact of introducing new DAAs at various levels of uptake in people infected with HCV genotype 1 using a stochastic agent-based dynamic transmission model.
Program
Operating Grant - Priority Announcement: Hepatitis C - biomedical/clinical
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
230584
Name
Thein Hla Hla
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Policy & Systems Management Research
Projecttitle
A pharmacoeconomic policy model for hepatitis C: development and applications
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$133,475
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Hepatitis C - biomedical/clinical
Keyworddelim
Antiviral Therapy; Burden Of Disease; Cost-Effectiveness Analysis; Economic Evaluation; Genetics; Health Policy; Hepatitis C Virus (Hcv); Personalised Medicine; Pharmacoeconomics; Transmission Modelling
Abstract
Hepatitis C virus (HCV) infection results in more lost life years than any other infectious disease in Ontario.1 The burden of HCV infection is growing in Canada.2,3 Existing preventive and therapeutic efforts are inadequate. However, the role of medications in disease control is not well appreciated. Current standard of care for chronic hepatitis C with pegylated interferon (PEG-IFN) alfa and ribavirin results in a cure (sustained virological response (SVR)) in less than half of people with HCV genotype 1 infection,4 which is the most prevalent genotype in Canada.5 Fewer than 15% of infected individuals have received treatment to date.6 There remains a huge burden of untreated HCV as well as those who failed previous treatment in Canada. The landscape of HCV therapy is changing because of the recent development of direct-acting antiviral agents (DAAs), with improved response rates and shorter and better tolerated therapy than the current standard of care, particularly for HCV genotype 1 infection. Therefore policymakers have complex challenges. Decision makers need to know if new medications should be paid for, while public health professionals need to incorporate the effects of treatment on disease control. Insights from mathematical modelling incorporating the effect of HCV treatment as a control strategy and model-based cost-effectiveness analysis (CEA) can support policy decision-makers and health service planners by predicting how much improvement in health can be expected for a given expenditure of resources. Our project aims to: i) evaluate the cost-effectiveness of DAA (telaprevir and boceprevir) therapeutic strategies in various clinical populations; and ii) evaluate the population health impact of introducing new DAAs at various levels of uptake in people infected with HCV genotype 1 using a stochastic agent-based dynamic transmission model.
Competitiondate
201103
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Thein, Hla Hla
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $133,475~ $0~
University of Toronto - $133,475 Grant (2010-11) | Canada Spends